Generation of E3-deleted canine adenovirus type 2 expressing the Gc glycoprotein of Seoul virus by gene insertion or deletion of related terminal region sequences

Yuan, Zihao; Luo, Shuhong; Xu, Hao; Wang, Xiaohu; Li, Juan; Yuan, Long; He, Liwen; Zhang, Xiu‐Xiang

doi:10.1099/vir.0.018473-0

Cited by 7 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The hantavirus glycoproteins are typically thought to be the principal targets of neutralizing antibodies (1,8,39,51), and although a few potential vaccine candidates have been evaluated with various degrees of success, largely in infection rather than disease models (2,7,10,21,24,25,35,56,60,72,73), the mechanism of protection against hantavirus infections remain unidentified. Here we constructed an attenuated, replication-competent recombinant VSV expressing the ANDV GPC in order to investigate its efficacy as a hantavirus vaccine in the Syrian hamster HPS disease model and to gain further insight into the mechanism of protection against lethal ANDV infection.…”

Section: Discussionmentioning

confidence: 99%

Vesicular Stomatitis Virus-Based Vaccine Protects Hamsters against Lethal Challenge with Andes Virus

Brown

Safronetz

Marzi

et al. 2011

J Virol

View full text Add to dashboard Cite

Andes virus (ANDV) is a highly pathogenic South American hantavirus that causes hantavirus pulmonary syndrome (HPS).A high case fatality rate, the potential for human-to-human transmission, the capacity to infect via aerosolization, and the absence of effective therapies make it imperative that a safe, fast-acting, and effective ANDV vaccine be developed. We generated and characterized a recombinant vesicular stomatitis virus (VSV) vector expressing the ANDV surface glycoprotein precursor (VSV⌬G/ANDVGPC) as a possible vaccine candidate and tested its efficacy in the only lethal-disease animal model of HPS. Syrian hamsters immunized with a single injection of VSV⌬G/ANDVGPC were fully protected against disease when challenged at 28, 14, 7, or 3 days postimmunization with a lethal dose of ANDV; however, the mechanism of protection seems to differ depending on when the immunization occurs. At 28 days postimmunization, a lack of detectable ANDV RNA in lung, liver, and blood tissue samples, as well as a lack of seroconversion to the ANDV nucleocapsidprotein in nearly all animals, suggested largely sterile immunity. The vaccine was able to generate high levels of neutralizing anti-ANDV G N /G C antibodies, which seem to play a role as a mechanism of vaccine protection. Administration of the vaccine at 7 or 3 days before challenge also resulted in full protection but with no specific neutralizing humoral immune response, suggesting a possible role of innate responses in protection against challenge virus replication. Administration of the vaccine 24 h postchallenge was successful in protecting 90% of hamsters and again suggested the induction of a potent antiviral state by the recombinant vector as a potential mechanism. Overall, our data suggest the potential for the use of the VSV platform as a fast-acting and effective prophylaxis/postexposure treatment against lethal hantavirus infections.

show abstract

Section: Discussionmentioning

confidence: 99%

Vesicular Stomatitis Virus-Based Vaccine Protects Hamsters against Lethal Challenge with Andes Virus

Brown

Safronetz

Marzi

et al. 2011

J Virol

View full text Add to dashboard Cite

show abstract

“…Using synthetic biology, it would be possible to produce DNA vaccine plasmids against all of the known pathogenic strains of hantaviruses; however, from a vaccine development perspective, this would be expensive, impractical, and unnecessary. We and others have demonstrated that neutralizing antibodies are sufficient to protect against infection and/or disease (14,15,31,37,38). Thus, the production of cross-neutralizing antibodies is a reasonable predictor that the vaccine will be cross-protective.…”

Section: Discussionmentioning

confidence: 99%

Construction and Nonclinical Testing of a Puumala Virus Synthetic M Gene-Based DNA Vaccine

Brocato

Josleyn

Wahl‐Jensen

et al. 2013

Clin Vaccine Immunol

View full text Add to dashboard Cite

“…Several techniques to construct recombinant AdVs, including CAdVs, have been reported. In vitro ligation or its improved method, in which foreign DNA is directly ligated to AdV DNA digested with restriction enzyme, requires a unique restriction enzyme site and has low ligation efficiency [ 11 , 12 , 13 , 14 ]. The mammalian cell-based homologous recombination method, in which foreign DNA flanked by homology arms and adenovirus DNA are introduced into cells, requires long homology arms and repeated plaque purifications [ 15 , 16 ].…”

Section: Introductionmentioning

confidence: 99%

“…However, any pre-existing cellular or humoral immunity against HAdV can prevent efficient gene transfer and affect the duration of gene expression. By contrast, humans do not have any pre-existing immunity Viruses 2020, 12, 767 2 of 14 against CAdVs [9], which presents CAdV-based vectors as promising for human use. Additionally, CAdV can potentially be an oncolytic virus for canine cancers [10].…”

Section: Introductionmentioning

confidence: 99%

Establishment of a Simple and Efficient Reverse Genetics System for Canine Adenoviruses Using Bacterial Artificial Chromosomes

Matsugo

Kobayashi-Kitamura

Kamiki

et al. 2020

Viruses

View full text Add to dashboard Cite

Canine adenoviruses (CAdVs) are divided into pathotypes CAdV1 and CAdV2, which cause infectious hepatitis and laryngotracheitis in canid animals, respectively. They can be the backbones of viral vectors that could be applied in recombinant vaccines or for gene transfer in dogs and in serologically naïve humans. Although conventional plasmid-based reverse genetics systems can be used to construct CAdV vectors, their large genome size creates technical difficulties in gene cloning and manipulation. In this study, we established an improved reverse genetics system for CAdVs using bacterial artificial chromosomes (BACs), in which genetic modifications can be efficiently and simply made through BAC recombineering. To validate the utility of this system, we used it to generate CAdV2 with the early region 1 gene deleted. This mutant was robustly generated and attenuated in cell culture. The results suggest that our established BAC-based reverse genetics system for CAdVs would be a useful and powerful tool for basic and advanced practical studies with these viruses.

show abstract

Generation of E3-deleted canine adenovirus type 2 expressing the Gc glycoprotein of Seoul virus by gene insertion or deletion of related terminal region sequences

Cited by 7 publications

References 29 publications

Vesicular Stomatitis Virus-Based Vaccine Protects Hamsters against Lethal Challenge with Andes Virus

Vesicular Stomatitis Virus-Based Vaccine Protects Hamsters against Lethal Challenge with Andes Virus

Construction and Nonclinical Testing of a Puumala Virus Synthetic M Gene-Based DNA Vaccine

Establishment of a Simple and Efficient Reverse Genetics System for Canine Adenoviruses Using Bacterial Artificial Chromosomes

Contact Info

Product

Resources

About